Professional
Added to YB: 2026-02-27
Pitch date: 2026-02-25
PPGN.SW [neutral]
PolyPeptide Group AG
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India.
Market Cap
CHF 893.7M
Pitch Price
CHF 25.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.14
P/E
-25.99
EV/Sales
2.52
Sector
Life Sciences Tools and Services
Category
growth
Pernas Research More Research Needed On: PolyPeptide Group AG
PPGN.SW (needs more research): Global CDMO for peptide/oligonucleotide therapeutics. CDMO model = leveraged exposure to drug innovation w/ high barriers & sticky customer relationships. Demand driven by rapid peptide medicine growth, esp. GLP-1s like Retatrutide (Phase 3). Revenue visibility post-launch. Performance tied to capacity utilization & new wins. Need to assess peptide supply/demand dynamics. EV/EBITDA 37x.
Read full article (1 min)